Scarica l'app Stockscreener
5.02
1.83%
0.09
Dopo l'orario di chiusura:
5.27
0.25
+4.98%
Precedente Chiudi:
$4.93
Aprire:
$4.93
Volume 24 ore:
169.11K
Relative Volume:
0.76
Capitalizzazione di mercato:
$75.40M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-0.8116
EPS:
-6.1852
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
+5.91%
1M Prestazione:
+26.45%
6M Prestazione:
-75.74%
1 anno Prestazione:
-78.19%
Intervallo 1D:
$4.92
$5.1999
Intervallo di 1 settimana:
$4.55
$5.1999
Portata 52W:
$3.1301
$26.84
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Confronta JSPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
5.02 | 71.20M | 0 | -64.47M | -52.33M | -6.1852 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Cantor Fitzgerald Brokers Lower Earnings Estimates for JSPR - Defense World
Oppenheimer Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $65.00 - Defense World
(JSPR) Trading Report - news.stocktradersdaily.com
William Blair Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q2 EPS Forecast for Jasper Therapeutics Increased by Analyst - Defense World
Jasper Therapeutics (JSPR) Price Target Lowered by Oppenheimer | JSPR Stock News - GuruFocus
Oppenheimer Cuts Price Target on Jasper Therapeutics to $65 From $80, Keeps Outperform Rating - marketscreener.com
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) - GuruFocus
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News - GuruFocus
Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development - Nasdaq
Jasper Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Jasper Therapeutics Showcases Novel Antibody Therapy at Major Healthcare Conferences This Summer - Stock Titan
UBS Maintains Buy Rating for Jasper Therapeutics (JSPR) Despite Price Target Adjustment | JSPR Stock News - GuruFocus
JSPR Price Target Adjusted by UBS Amidst Upcoming Clinical Updates | JSPR Stock News - GuruFocus
Jasper (JSPR) Advances Briquilimab with Promising Trial Results - GuruFocus
UBS Adjusts Price Target on Jasper Therapeutics to $33 From $38, Maintains Buy Rating - marketscreener.com
Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs - TipRanks
Jasper Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics (JSPR) to Release Quarterly Earnings on Tuesday - Defense World
Wells Fargo & Company MN Purchases 3,828 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $62.50 - Defense World
JPMorgan Chase & Co. Sells 11,226 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
(JSPR) Trading Advice - news.stocktradersdaily.com
Global Fanconi Anemia Market Insights: Jasper Therapeutics, - openPR.com
(JSPR) Investment Analysis and Advice - news.stocktradersdaily.com
Statement of Ownership (sc 13g) - ADVFN
Wellington Management Group LLP Boosts Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Analysts - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 19.7% in March - Defense World
JSPR stock touches 52-week low at $4.54 amid market challenges By Investing.com - Investing.com South Africa
JSPR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Jasper Therapeutics Inc Files For Common Stock Offering Of Up To $100 MillionSEC Filing - MarketScreener
Urticaria Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Sanofi, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, Roche, Novartis, GSk - Barchart.com
DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World
Jasper Therapeutics inks new sales agreement, ends previous deal By Investing.com - Investing.com South Africa
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $62.50 - Defense World
Jasper Therapeutics inks new sales agreement, ends previous deal - Investing.com
Jasper Therapeutics Files $300 Million Mixed Shelf -March 19, 2025 at 05:08 pm EDT - Marketscreener.com
Jasper Therapeutics Signs New Sales Agreement with Jefferies - TipRanks
Jasper Therapeutics terminates Cantor sales agreement -March 19, 2025 at 04:53 pm EDT - Marketscreener.com
Jasper Therapeutics files for mixed shelf offering of up to $300 mln -March 19, 2025 at 04:17 pm EDT - Marketscreener.com
(JSPR) On The My Stocks Page - news.stocktradersdaily.com
Jasper Therapeutics’ (JSPR) Buy Rating Reiterated at HC Wainwright - Defense World
Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics - TipRanks
FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald - Defense World
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains Buy rating, $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones - TipRanks
Jasper Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Equities Analysts Set Expectations for JSPR Q1 Earnings - Defense World
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):